INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

The court award does not assure payment: INOVIO expects the defendants' financial condition to limit recovery.

Rhea-AI Summary

INOVIO Pharmaceuticals (Nasdaq: INO) secured an $80,416,101 judgment in its favor against VGXI and GeneOne Life Science on all its claims.

The Court of Common Pleas of Montgomery County, Pennsylvania, awarded $61,750,789 in compensatory damages and $18,665,312 in fees and costs. It also entered judgment against the defendants on their counterclaims. The case was filed on June 3, 2020. INOVIO expects the defendants' financial condition to impair collection of some or all of the judgment and intends to make every reasonable effort to recover the damages awarded.

2 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point$80,416,101 judgment awarded to INOVIO on all its claims against VGXI and GeneOne Life Science. 78% of market cap
• Minor pointDefendants' counterclaims also resulted in judgment against them.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Collection risk: INOVIO expects defendants' financial condition to impair recovery of some or all of the judgment.

Argus 15 min delay 30 alerts

+9.90% vs previous close $1.11 last price 2.9x rel. volume Open Argus

Details

Market Reaction – INO

+21.5% Peak Tracked

-4.7% Trough Tracked

$0.97 – $1.41 Day Range

$114.77M Mkt Cap at Last Price

On Oct 20, the day this news came out, the latest delayed price for INO is 9.90% above the previous close. Argus tracked a peak move of +21.5% during the session. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner has recorded 30 alerts for this stock so far that day. The latest delayed price is $1.11. Relative volume is elevated at 2.9x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Total judgment: $80,416,101 Compensatory damages: $61,750,789 Fees and costs: $18,665,312

Total judgment

$80,416,101

Awarded to INOVIO in litigation with VGXI and GeneOne

Compensatory damages

$61,750,789

Component of the judgment

Fees and costs

$18,665,312

Component of the judgment

Key Terms

compensatory damages, dna plasmids

2 terms

compensatory damages financial

"The Court awarded INOVIO $61,750,789 in compensatory damages"

Compensatory damages are money a company may be required to pay to make up for real losses caused by its actions or failures, either as a court award or as part of a settlement. Think of it as a repair bill that covers direct harm—lost profits, medical costs, property damage—or reasonable replacement costs; investors watch these amounts because they can reduce cash, hurt earnings and signal legal or operational risks that affect valuation and future earnings.

dna plasmids technical

"enable scalable manufacturing of DNA plasmids"

Circular, double‑stranded DNA molecules that exist independently of a cell’s chromosomes and can replicate on their own; they are commonly used as carriers to add, express, or manipulate genes inside bacteria, mammalian cells, or cell-free systems. Plasmids are often engineered to include control elements (promoters, selectable markers) so researchers or manufacturers can produce specific proteins, study gene function, or deliver genetic material, and they differ from chromosomal DNA in being nonessential to the host and transferable between cells.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc. ("VGXI") and GeneOne Life Science, Inc. ("GeneOne") in the case captioned INOVIO Pharmaceuticals, Inc. v. VGXI, Inc. and GeneOne Life Science, Inc., No. 2020-06554, in the Court of Common Pleas of Montgomery County, Pennsylvania. The Court awarded INOVIO $61,750,789 in compensatory damages and $18,665,312 in fees and costs. The Court also entered judgment against defendants on their counterclaims.

INOVIO filed the case on June 3, 2020, when defendants breached the parties' Supply Agreement by refusing to honor their technology transfer obligations to enable scalable manufacturing of DNA plasmids.

Defendants' financial condition will likely impair INOVIO's ability to collect some or all of the judgment. INOVIO intends to use every reasonable effort to recover the damages awarded by this judgment.

Cooley LLP and FBT Gibbons served as trial counsel for INOVIO.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.

Forward-Looking Statements

This press release contains certain forward-looking statements relating to INOVIO's business, including statements regarding INOVIO's ability to collect on and realize the ultimate value from the judgment entered in INOVIO's favor against VGXI and GeneOne and the impact of defendants' financial condition on INOVIO's ability to enforce or collect any portion of the judgment. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including the risk that the judgment may be reduced, reversed, or otherwise modified on post-trial motions or appeal; the risk that defendants' financial condition will likely impair INOVIO's ability to collect some or all of the judgment, associated interest, fees and costs, notwithstanding INOVIO's intent to use every reasonable effort to recover the damages awarded; the time, expense, and uncertainty associated with collection and enforcement efforts; the adequacy of INOVIO's capital resources; the level of corporate expenditures; capital market conditions; and other factors set forth in INOVIO's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings INOVIO makes from time to time with the Securities and Exchange Commission. There can be no assurance that INOVIO will collect any or all of the judgment, that the judgment will not be reduced, reversed, or otherwise modified, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and INOVIO undertakes no obligation to update or revise these statements, except as may be required by law.

Contacts

Media: Josephine Galatioto, ICR Healthcare, inoviopr@icrhealthcare.com
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-announces-favorable-judgment-in-litigation-with-vgxi-inc-and-geneone-life-science-302914515.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did INOVIO win in the VGXI and GeneOne litigation?

INOVIO secured a judgment of $80,416,101 against VGXI and GeneOne Life Science. The award comprises $61,750,789 in compensatory damages and $18,665,312 in fees and costs. The court also entered judgment against the defendants on their counterclaims.